两名患有难治性坏疽性脓皮病和化脓性汗腺炎的患者对白细胞介素-1拮抗剂卡那单抗无反应。
Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa.
作者信息
Sun Natalie Z, Ro Teresa, Jolly Puneet, Sayed Christopher J
机构信息
All authors are with the University of North Carolina at Chapel Hill, Dermatology, in Chapel Hill, North Carolina.
出版信息
J Clin Aesthet Dermatol. 2017 Sep;10(9):36-38. Epub 2017 Sep 1.
Abstract
Pyoderma gangrenosum and hidradenitis suppurativa are skin conditions characterized by an intense neutrophil-mediated inflammatory response that is often difficult to effectively treat. Successful use of interleukin (IL)-1β inhibition using canakinumab and anakinra has been reported in patients with concomitant pyoderma gangrenosum and hidradenitis suppurativa. We report two cases where targeted therapy with canakinumab failed to lead to improvement for patients with pyoderma gangrenosum and hidradenitis suppurativa. The reason behind the non-response to IL-1β blockade seen in these patients is unclear. Our report suggests that further controlled studies are warranted to help clinicians predict treatment responses to anti-IL-1 therapies in these challenging patients.
摘要
坏疽性脓皮病和化脓性汗腺炎是皮肤疾病，其特征为强烈的中性粒细胞介导的炎症反应，通常难以有效治疗。据报道，使用卡那单抗和阿那白滞素抑制白细胞介素（IL）-1β 可成功治疗合并坏疽性脓皮病和化脓性汗腺炎的患者。我们报告了两例使用卡那单抗进行靶向治疗未能改善坏疽性脓皮病和化脓性汗腺炎患者病情的病例。这些患者对IL-1β 阻断无反应的原因尚不清楚。我们的报告表明，有必要进行进一步的对照研究，以帮助临床医生预测这些具有挑战性的患者对抗IL-1疗法的治疗反应。
相似文献
1
Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa.两名患有难治性坏疽性脓皮病和化脓性汗腺炎的患者对白细胞介素-1拮抗剂卡那单抗无反应。
J Clin Aesthet Dermatol. 2017 Sep;10(9):36-38. Epub 2017 Sep 1.
2
Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome: A Case Report and Literature Review.坏疽性脓皮病、痤疮和化脓性汗腺炎综合征：一例报告及文献综述
Front Med (Lausanne). 2022 Mar 24;9:856786. doi: 10.3389/fmed.2022.856786. eCollection 2022.
3
Pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH) syndrome with recurrent vasculitis.伴有复发性血管炎的坏疽性脓皮病、痤疮和化脓性汗腺炎（PASH）综合征
JAAD Case Rep. 2017 Feb 4;3(1):70-73. doi: 10.1016/j.jdcr.2016.11.006. eCollection 2017 Jan.
4
Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne.与化脓性汗腺炎和/或痤疮相关的自身炎症性综合征。
Int J Dermatol. 2017 Aug;56(8):811-818. doi: 10.1111/ijd.13603. Epub 2017 Mar 27.
5
Successful combined antibiotic therapy with oral clindamycin and oral rifampicin for pyoderma gangrenosum in patient with PASH syndrome.口服克林霉素和口服利福平联合抗生素治疗PASH综合征患者坏疽性脓皮病取得成功。
JAAD Case Rep. 2017 Dec 18;4(1):17-21. doi: 10.1016/j.jdcr.2017.05.005. eCollection 2018 Jan.
6
Pyoderma gangrenosum and suppurative hidradenitis association, overlap or spectrum of the same disease? Case report and discussion.坏疽性脓皮病与化脓性汗腺炎的关联、重叠还是同一疾病的不同表现？病例报告与讨论。
Exp Ther Med. 2020 Jul;20(1):38-41. doi: 10.3892/etm.2019.8150. Epub 2019 Oct 30.
7
Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome: a single-institution case series with a focus on management.坏疽性脓皮病、痤疮和化脓性汗腺炎（PASH）综合征：单机构病例系列，重点关注治疗。
Arch Dermatol Res. 2024 Jun 15;316(7):397. doi: 10.1007/s00403-024-03125-7.
8
9
Pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) and polycystic ovary syndrome: Coincidentally or aetiologically connected?坏疽性脓皮病、痤疮、化脓性汗腺炎（PASH）与多囊卵巢综合征：是巧合还是存在病因学关联？
Australas J Dermatol. 2017 May;58(2):e54-e59. doi: 10.1111/ajd.12438. Epub 2016 Feb 2.
10
A complex case of PASH syndrome: pyoderma gangrenosum, acne, suppurative hidradenitis, and Crohn's disease in a 36-year-old smoker.一例复杂的PASH综合征病例：一名36岁吸烟者同时患有坏疽性脓皮病、痤疮、化脓性汗腺炎和克罗恩病。
Ann Med Surg (Lond). 2024 Sep 5;86(10):6280-6284. doi: 10.1097/MS9.0000000000002533. eCollection 2024 Oct.
引用本文的文献
1
Trained Immunity and Its Potential Implications in the Etiopathogenesis of Hidradenitis Suppurativa: A New Paradigm in Chronic Inflammation?训练有素的免疫及其在化脓性汗腺炎病因发病机制中的潜在影响：慢性炎症的新范式？
Exp Dermatol. 2025 Aug;34(8):e70160. doi: 10.1111/exd.70160.
2
Essentials of hidradenitis suppurativa: a comprehensive review of diagnostic and treatment perspectives.化脓性汗腺炎要点：诊断与治疗观点的全面综述
Ann Med Surg (Lond). 2024 Jul 1;86(9):5304-5313. doi: 10.1097/MS9.0000000000002345. eCollection 2024 Sep.
3
Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human.细胞因子在特应性皮炎病理生理学中的相互作用：来自小鼠模型和人类的见解。
Front Med (Lausanne). 2024 Mar 25;11:1342176. doi: 10.3389/fmed.2024.1342176. eCollection 2024.
4
Therapeutic Potential of IL-1 Antagonism in Hidradenitis Suppurativa.白细胞介素-1 拮抗剂在化脓性汗腺炎中的治疗潜力。
Biomolecules. 2024 Feb 1;14(2):175. doi: 10.3390/biom14020175.
5
Pathological and Therapeutical Implications of Pyroptosis in Psoriasis and Hidradenitis Suppurativa: A Narrative Review.焦亡在银屑病和化脓性汗腺炎中的病理及治疗意义：一项叙述性综述
Curr Issues Mol Biol. 2024 Jan 11;46(1):663-676. doi: 10.3390/cimb46010043.
6
Hidradenitis suppurativa and psoriasis: the odd couple.化脓性汗腺炎与银屑病：这一奇特组合。
Front Med (Lausanne). 2023 Jul 7;10:1208817. doi: 10.3389/fmed.2023.1208817. eCollection 2023.
7
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
8
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
9
Current Medical and Surgical Treatment of Hidradenitis Suppurativa-A Comprehensive Review.化脓性汗腺炎的当前医学与外科治疗——综述
J Clin Med. 2022 Dec 6;11(23):7240. doi: 10.3390/jcm11237240.
10
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
本文引用的文献
1
Canakinumab in adults with steroid-refractory pyoderma gangrenosum.卡那奴单抗治疗类固醇难治性坏疽性脓皮病的成人患者。
Br J Dermatol. 2015 Nov;173(5):1216-23. doi: 10.1111/bjd.14037. Epub 2015 Oct 16.
2
Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant.肿瘤坏死因子受体相关周期性综合征治疗中的喜与忧：卡那单抗治疗携带高穿透性T50M TNFRSF1A变异患者的经验
Int J Rheum Dis. 2015 May;18(4):473-5. doi: 10.1111/1756-185X.12521. Epub 2014 Dec 18.
3
Successful treatment of severe hidradenitis suppurativa with anakinra.用阿那白滞素成功治疗重度化脓性汗腺炎。
JAMA Dermatol. 2013 Oct;149(10):1192-4. doi: 10.1001/jamadermatol.2013.5377.
4
Pyoderma gangrenosum and concomitant hidradenitis suppurativa--rapid response to canakinumab (anti-IL-1β).坏疽性脓皮病合并化脓性汗腺炎——对卡那单抗（抗IL-1β）快速反应
Eur J Dermatol. 2013 May-Jun;23(3):408-10. doi: 10.1684/ejd.2013.2018.
5
Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome.坏疽性脓皮病、痤疮和化脓性汗腺炎（PASH）——一种不同于 PAPA 综合征的新型自身炎症性综合征。
J Am Acad Dermatol. 2012 Mar;66(3):409-15. doi: 10.1016/j.jaad.2010.12.025. Epub 2011 Jul 13.
6
Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review.化脓性汗腺炎合并坏疽性脓皮病：病例系列及文献综述
Arch Dermatol. 2010 Nov;146(11):1265-70. doi: 10.1001/archdermatol.2010.328.
7
Hidradenitis suppurativa: a comprehensive review.化脓性汗腺炎：一项全面综述。
J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3. doi: 10.1016/j.jaad.2008.11.911.
8
Pyoderma gangrenosum--a review.坏疽性脓皮病——综述
Orphanet J Rare Dis. 2007 Apr 15;2:19. doi: 10.1186/1750-1172-2-19.
9
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.英夫利昔单抗治疗坏疽性脓皮病：一项随机、双盲、安慰剂对照试验。
Gut. 2006 Apr;55(4):505-9. doi: 10.1136/gut.2005.074815. Epub 2005 Sep 27.
10
Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab.化脓性汗腺炎与克罗恩病：英夫利昔单抗治疗反应
Inflamm Bowel Dis. 2001 Nov;7(4):323-6. doi: 10.1097/00054725-200111000-00008.
Zotero 插件